Navigation Links
Vascular in Medical Technology

Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients

Clinical Data Presented at the 2009 ASCO Meeting INDIANAPOLIS, May 30 /PRNewswire/ -- Semafore Pharmaceuticals, Inc., a privately held cancer drug discovery and development company, today presented data from a Phase I clinical trial of its vascular targeted pan-PI3K/mTORC1/2 inhibitor, SF1126...

Lower Extremity Peripheral Vascular Stent and Balloon Catheter Markets to Exceed $180 Million in Europe by 2013

Positive clinical data, competitor focus, and new drug-eluting technologies to drive lower extremity procedures in Europe , according to Millennium Research Group WALTHAM, Mass., May 28 /PRNewswire/ -- According to Millennium Research Group's (MRG's) European Markets for Peripheral Vasc...

Clinical Data on Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, to be Presented at the 2009 ASCO Meeting

INDIANAPOLIS, May 19 /PRNewswire/ -- Semafore Pharmaceuticals, Inc., a privately held cancer drug discovery and development company, today announced that it will be reporting Phase I clinical data on its vascular targeted pan-PI3K/mTORC1/2 inhibitor, SF1126, during the 2009 American Society of Cli...

New Research Suggests Platelet 'Stickiness' May be the Single Most Important Risk Factor in Patients Treated with Coronary Stents - Findings May be Applicable to Anyone with Vascular Disease

BALTIMORE, Jan. 27 /PRNewswire/ -- Most Americans know their cholesterol level, but do they know how "sticky" their platelets are? Research findings from Dr. Paul A. Gurbel, an interventional cardiologist and Director of the Sinai Center for Thrombosis Research based at Sinai Hospital of Baltimor...

Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting Antibodies

-Combination of a Bavituximab Equivalent and an Agent that Re-Activates the Tumor Suppressor P53 Inhibited Tumor Growth Synergistically in Preclinical Breast Cancer Models- SAN DIEGO and TUSTIN, Calif., April 14 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (...

Semafore's PI3 Kinase Inhibitor SF1126 is a Vascular Targeted Conjugate in Phase I Clinical Trials in Solid Tumors and Multiple Myeloma

SAN DIEGO, April 14 /PRNewswire/ -- Semafore Pharmaceuticals Inc. announced today on the occasion of a poster presentation at the 2008 AACR Annual Meeting that its integrin-targeted PI3 kinase inhibitor, SF1126, was shown to cause significant tumor regression in combination with rapamycin in a...

VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation

- Comprehensive Phase 2 Program to Provide Initial Proof-of-Concept Data This Year - SAN FRANCISCO, Jan. 7 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals (Nasdaq: VIAP ), a biotechnology company focused on the development of compounds for the treatment of cardiovas...

Not Only Lipids and Inflammation: Insight Into a New Cause of Heart Attack and Other Vascular Disease

REYKJAVIK, Iceland, Jan. 6 /PRNewswire/ -- deCODE scientists today report that the genetic variant on chromosome 9p21 that the company has linked to increased risk of heart attack is also associated with up to 70% increase in risk of abdominal aortic aneurysm (AAA) and intracranial aneurysm (I...

Abbott to Present New Data Across its Vascular Portfolio at the American College of Cardiology's 56th Annual Scientific Session

Highlights Include First U.S. Clinical Data on XIENCE V Everolimus Eluting Coronary Stent System and Six-Month Patient Follow-Up Results from the ABSORB Bioabsorbable Stent Clinical Study ABBOTT PARK, Ill., March 19, 2007 /PRNewswire-FirstCall/ -- Abbott will present data from several stud...

Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh to be Presented at European Vascular Symposium

STRASBOURG, France and VANCOUVER, April 26, 2007 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. , a global specialty pharmaceutical and medical device company, announced that the two-year data from its European pivotal trial examining the Vascular Wrap(TM) Paclitaxel-Eluting Mesh ("Vascu...

Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease

Adult stem cells cultivated from patients' own blood can potentially improve the quality of life for patients whose lower extremities are affected by peripheral vascular disease, according to a study in China. SHENZHEN, China, July 02, 2007 /PRNewswire/ -- Beike Biotechnology Co., Ltd. (

Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease

DENVER--(BUSINESS WIRE)--Jul 10, 2007 - Corgenix Medical Corporation (OTC BB: CONX) and the Company's clinical collaborators reported new clinical data demonstrating a significant correlation between serum levels of the Company's patented AtherOx(TM) bio-markers and cardiovascular disease. The data...

2,500 Cases Completed With the Magnetic Irrigated Catheter

...ures in patients with congenital heart defects and patients with peripheral vascular occlusive disease. Altogether this represents the broadest range of cardio... magnetic navigation technology as a platform for all manner of cardiac and vascular interventions," said Michael P. Kaminski, Stereotaxis President and CEO. "S...

Terumo Cardiovascular Systems Initiates U.S. Clinical Trial for Anaconda(TM) AAA Stent Graft System

...n April 2005. According to the Society of vascular Surgery, physicians diagnose approximately 200,000...market and is the U.S. distributor for Vascutek(R) vascular Grafts. The company is headquartered in Ann Arbor...f Japan that is focused exclusively on cardiac and vascular specialties, including Terumo Heart Inc., develope...

Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study

...iabetes-statistics/cost-of-diabetes-in-us.jsp. Accessed July 13, 2009. (iv) Saydah SH, Fradkin J and Cowie CC. "Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes." JAMA : 291(3), January 21, 2004. (v) Bays HE, Chapman RH, Grandy S. The relationship o...

St. Francis Surgeon Uses Tissue Regeneration Technology to Rebuild Patients' Heart Structures

...n call toll-free at 1-866-237-0565. The St. Francis Heart Center is dedicated to providing our patients with the region's most comprehensive heart and vascular services. The commitment of our physicians to the prevention and cure of heart disease has led to innovative care, better outcomes and improved qualit...

ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402

... ThromboGenics is a biotechnology company focused on the discovery and development of innovative biopharmaceuticals for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye dis...

ThromboGenics' Microplasmin Phase III Program Progressing According to Schedule

... on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that its lead product microplasmin, whi...elopment of innovative biopharmaceuticals for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III...

Roskamp Institute Announces Enrollment of First Students to Participate in its Innovative Research Doctorate Program

...a with a Bachelor of Science in Nutritional Science, is building on the seminal work of lead Institute scientists by exploring the mechanisms linking vascular factors to the development of Alzheimer's disease. OU has a 110 acre campus in Milton Keynes, England, and is also a distance learning university...

Published Study Shows VNUS ClosureFAST(TM) System Significantly Superior to Laser for Varicose Vein Treatment

... Journal of vascular & Interventional Radiology Cites Improved Recovery and Quality-of-Life ...treatment of venous reflux disease , announced today that the Journal of vascular & Interventional Radiology, the prestigious monthly publication of the ...

Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009

...diabetes-statistics/cost-of-diabetes-in-us.jsp . Accessed March 28, 2009. (iv) Saydah SH, Fradkin J and Cowie CC. "Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes." JAMA: 291(3), January 21, 2004. (v) Bays HE, Chapman RH, Grandy S. The relationship of bo...

Heparin Use Prior to Endoscopic Vein Harvest Improves Graft Patency in Off-Pump Coronary Artery Bypass Patients

...ecently formed by combining MAQUET Cardiopulmonary with Boston Scientific's vascular Surgery and Cardiac Surgery divisions, which includes the products and serv...opic vessel harvesting, off- and on-pump coronary artery bypass surgery and vascular grafts. MAQUET has 170 years of healthcare experience, and is committe...

Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial

...inion supporting EU approval of Afinitor to treat patients with advanced renal cell carcinoma, whose disease has progressed on or after treatment with vascular endothelial growth factor (VEGF)-targeted therapy. In cancer cells, Afinitor continuously targets mTOR, a protein that acts as a central regulato...

Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009

...betes-statistics/cost-of-diabetes-in-us.jsp . Accessed March 28, 2009. (iv) Saydah SH, Fradkin J and Cowie CC. "Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes." JAMA: 291(3), January 21, 2004. (v) Bays HE, Chapman RH, Grandy S. The relationship of...

Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes

...://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf Accessed May 13, 2009 (3) Saydah SH, Fradkin J and Cowie CC. "Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes." JAMA: 291(3), January 21, 2004 (4) Centers for Disease Control and Prevention. "Nation...

PARI Pharma Reports Successful Phase Ib Clinical Results for Inhaled Liposomal Cyclosporine A and Gains FDA Orphan Drug Designation for the Prevention and Treatment of Bronchiolitis Obliterans

...hich manifests as chronic allograft rejection and results in airflow obstruction. The disease is also a factor in other lung diseases such as collagen vascular diseases, inhalation of toxic fumes, and respiratory tract infections. Bronchiolitis obliterans affects approximately 60,000 patients worldwide, and o...

CardioVascularCS.Org, a division of EndoVascular Forum, Inc., Partners with Complex Interventional Cardiovascular Therapy (CICT) to Extend Electronic Medical Care Advancement

...ision-making in the field of Interventional Cardiovascular Medicine. CICT will accomplish its mission by creating a Forum where experts in cardiac and vascular interventions share their experiences with an audience of their peers through interactive complex case presentations. This forum will encourage open a...

PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference

...eptor, currently in a Phase I clinical trial and intended for subsequent development to treat diseases such as Type 2 diabetes, multiple sclerosis and vascular restenosis, and CCX354, a CCR1 antagonist in a Phase I clinical trial, being developed for inflammatory diseases such as rheumatoid arthritis. ChemoC...

Kensey Nash Announces Presentations on its Cartilage Repair Device at the International Cartilage Repair Society Meeting

...ialize technologies. The Company is known as a pioneer in the field of arterial puncture closure, as the inventor and developer of the Angio-Seal(TM) vascular Closure Device, which is licensed to St. Jude Medical, Inc. Cautionary Note for Forward-Looking Statements . This press release contains forwar...

Bethesda-Based NHSi Wins $2M Grant for Blood Technology

... Sciences: NHSi is a privately held company that is developing and commercializing two, strategically linked technologies. The first, Hemodyanamic vascular Analysis (" HVA "), is a proprietary software and data-based diagnostic and disease management platform. HVA addresses a large and growing need in ne...

PARI Pharma's Nebulized DSCG Shows Results Similar to Inhaled Steroids in Asthma Studies Presented at ATS

...antiviral potency of DSCG. "Since the relevance of mast cells in lung vascular remodeling and the development of pulmonary hypertension was also demonstra...nt of pulmonary hypertension," stated Dr. Wolfgang M. Kuebler, professor of vascular physiology and pathophysiology at the Charite University Hospital, Berlin, ...

Boston Scientific Begins Clinical Trial for Next-Generation Nitinol Stent to Treat Iliac Artery Disease

...dard in the treatment of iliac arterial disease," said Daniel Clair, M.D., FACS, Principal Investigator of the trial and Chairman of the Department of vascular Surgery, The Cleveland Clinic Foundation. "The ORION clinical trial will provide important data on the performance of the EPIC Stent in the treatment...

Long Term Data Presented at EuroPCR 2009 from Randomized Study Attest to Durability of Results of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Compared to Drug-Eluting Stents

...combined with our coating technologies, we will be able to achieve clinical vascular restoration therapies simply not possible with metal." Unlike drug-e...s, manufactures and markets innovative medical devices for the treatment of vascular diseases. Other products in the company's product portfolio are stents, ba...

Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent

...g the right treatment for patients with challenging coronary lesions," said Dean J. Kereiakes, M.D., Medical Director at The Christ Hospital Heart and vascular Center and The Lindner Research Center in Cincinnati, Ohio and a principal investigator for the TAXUS PERSEUS clinical trial evaluating the TAXUS Elem...

PLC Medical Systems to Demonstrate RenalGuard(R) at EuroPCR 2009

...c. (OTC Bulletin Board: PLCSF), a company focused on innovative cardiac and vascular medical device-based technologies, today announced that it will demonstrate...hnology company specializing in innovative technologies for the cardiac and vascular markets. Headquartered in Franklin, Massachusetts, PLC pioneered the CO2 H...

Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009

...11) BIBF 1120 is an oral compound that works by simultaneously inhibiting vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth facto...Phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 followign treatment of relapsed ovarian cancer (O...

Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results

...tion, angiotensin II stimulates the release of another hormone that causes enhanced sodium and chloride (salt) retention, with a resultant increase in vascular water retention and blood volume that also contributes to an elevation in blood pressure. Olmesartan medoxomil is a member of the ARB class of antihyp...

New Data Shows Blood Pressure Reduction Therapy with BENICAR(R) and BENICAR HCT(R) Effectively Reduces Blood Pressure in Elderly Patients to Target Blood Pressure

...tion, angiotensin II stimulates the release of another hormone that causes enhanced sodium and chloride (salt) retention, with a resultant increase in vascular water retention and blood volume that also contributes to an elevation in blood pressure. BENICAR is a member of the ARB class of antihypertensive med...

Corgenix, Tulane Announce Award of NIH Grant Extending Hemorrhagic Fever Virus Product Development Program

...ical Corporation Corgenix (Denver, Colo.) is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases, bone and joint disorders. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company...

Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine

...mparable safety profile," said Gregg W. Stone, M.D., Professor of Medicine and the Director of Research and Education at the Center for Interventional vascular Therapy at the Columbia University Medical Center/New York-Presbyterian Hospital and Principal Investigator of the trial. "This is the first ...
Other Tags
(Date:4/18/2014)... feeding a world population predicted to reach 9 ... to conservation that considers human-altered landscapes such as ... the natural habitat that supports it might be ... at least three-quarters of the land surface is ... vulnerable to human-caused impacts such as climate change. ...
(Date:4/18/2014)... that sprout as soon as they,re planted may be good ... more careful. In the wild, a plant whose seeds sprouted ... disaster. More than just an insurance policy against late frosts ... has long-term advantages too: Plants whose seeds put off ... species, finds in a team of researchers working at the ...
(Date:4/17/2014)... densely forested and most densely populated quadrant of the ... values and practices. Disturbances associated with those needs, such ... have set the stage for management issues of considerable ... The report Five anthropogenic factors that will radically ... United States was published recently by the ...
Breaking Biology News(10 mins):Stanford researchers rethink 'natural' habitat for wildlife 2Stanford researchers rethink 'natural' habitat for wildlife 3Stanford researchers rethink 'natural' habitat for wildlife 4Plants with dormant seeds give rise to more species 2Five anthropogenic factors that will radically alter northern forests in 50 years 2Five anthropogenic factors that will radically alter northern forests in 50 years 3
(Date:4/17/2014)... new pain relief targets that could be used ... at King,s College London made the discovery when ... periphery of the body. , Dr Marzia Malcangio ... underlying pain generation and our findings could help ... , One potential side effect of some chemotherapy ...
(Date:4/17/2014)... April issue of Experimental Biology and Medicine ... Rex Gaskins and Paul Kenis in the Institute ... the University of Illinois Urbana-Champaign describe their recent ... underlie a variety of cell functions including energy ... crucial roles in regulating normal cellular behavior, redox ...
(Date:4/17/2014)... MANHASSET, NY In a review published in the ... MD, president of The Feinstein Institute for Medical Research, ... the medical community,s approach to treating sepsis, ... 200,000 Americans. , Sepsis occurs when molecules released into ... inflammation throughout the body. Inflammation is necessary for maintaining ...
(Date:4/17/2014)... personnel who served in Iraq and Afghanistan and ... (TBI) were compared to military personnel without TBI ... in measures of overall disability, cognitive function, post-traumatic ... reported in an article in Journal of ... Liebert, Inc., publishers. The article is available free ...
(Date:4/17/2014)... The cause of neuronal death in Parkinson,s disease ... neurons may be mistaken for foreign invaders and killed ... way autoimmune diseases like type I diabetes, celiac disease, ... was published April 16, 2014, in Nature Communications ... idea in Parkinson,s disease; but if true, it could ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Is Parkinson's an autoimmune disease? 2
Other Contents